About ACM Biolabs
ACM Biolabs is a company based in Singapore (Singapore) founded in 2012 by Madhavan Nallani. ACM Biolabs offers products and services including ATP™ Platform. ACM Biolabs operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, GSK, Avidity Biosciences and Generate Biomedicines, among others.
- Headquarter Singapore, Singapore
- Founders Madhavan Nallani
- SectorsHealthcareChemicals & Materials
- Website acmbiolabs.com
- Social LinkedIn
- Legal Name Acm Biolabs Pte. Ltd.
- Annual Revenue$33.72 K (USD)0as on May 31, 2018
- Net Profit-$1.02 M (USD)2as on May 31, 2019
- InvestorsNTUitive
& 1 more
Products & Services of ACM Biolabs
ACM Biolabs offers a comprehensive portfolio of products and services, including ATP™ Platform.
Hybrid platform for targeted delivery of drug payloads like mRNA and proteins.
Funding Insights of ACM Biolabs
- Total Rounds 2
- Investors Count 2
All 2 funding rounds of ACM Biolabs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | – | Seed | – | Venturelab | – |
| Apr 2016 | – | Seed | – | NTUitive | – |
2 investors in total: 2 institutional.
Investors in ACM Biolabs
ACM Biolabs has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include NTUitive and Venturelab.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Startups across technologies and sectors are incubated by university-backed NTUitive. | – | ntuitive.sg | Singapore, Singapore | |
Swiss startups are supported through innovative programs by Venturelab. | 2004 | venturelab.ch | Switzerland |
Investor details for ACM Biolabs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ACM Biolabs
1 people are tracked at ACM Biolabs (1 in leadership).
| Name | Role | Group |
|---|---|---|
Madhavan Nallani | Founder & CEO | Leadership |
Complete people profiles for ACM Biolabs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ACM Biolabs
3 dated milestones of ACM Biolabs across 9 years, from founding to its latest funding, stage changes and deals.
- Founded ACM Biolabs is founded.
- Funding First funding round.
- Funding Latest funding round, Seed,.
Competitors of ACM Biolabs
ACM Biolabs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, GSK, Avidity Biosciences and Generate Biomedicines, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| hookipapharma.com | 2011 | Vienna, Austria | $133.72M | – | Developer of immunotherapies for the treatment of infectious diseases and cancer | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of ACM Biolabs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ACM Biolabs
The website of ACM Biolabs (acmbiolabs.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▼ 27.5% vs previous month
Latest news on Acm Biolabs
Complete news archive for ACM Biolabs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ACM Biolabs
10 companies that operate in the same segment as ACM Biolabs (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ACM Biolabs
ACM Biolabs was founded in 2012 and raised its 1st funding round 4 years after it was founded.
ACM Biolabs is headquartered in Singapore, Singapore.
Madhavan Nallani is the current CEO of ACM Biolabs. They have also founded this company.
Annual revenue of ACM Biolabs is $33.72K as on May 31, 2018.
ACM Biolabs was founded in 2012 in Singapore within the biotechnology sector. A proprietary artificial polymer-based cell membrane platform has been developed to embed and stabilize functional membrane proteins in environments mimicking native conditions. This technology supports vaccine development by eliciting immune responses and facilitates antibody production targeting membrane proteins. Additionally, targeted drug delivery systems for ocular and transdermal applications are being explored.
ACM Biolabs's top competitors include Moderna, Sutro Biopharma and Adaptive Biotechnologies.
ACM Biolabs offers ATP™ Platform.
ACM Biolabs has 2 investors. Key investors include NTUitive, and Venturelab.
ACM Biolabs operates through Acm Biolabs Pte. Ltd..